Sickle cell bone disease: Response to vitamin D and calcium

American Journal of Hematology

Volumn 83, Issue 4, 2008, Pages 271-274

  Adewoye, Adeboye H ^a   Chen, Tai C ^a   Ma, Qianli ^a   McMahon, Lillian ^a   Mathieu, Jeff ^a   Malabanan, Alan ^b   Steinberg, Martin H ^a   Holick, Michael F ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIFEDIOL; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; ERGOCALCIFEROL; OSTEOCALCIN;

ADULT; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MALE; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; PRIORITY JOURNAL; RADIUS; SICKLE CELL ANEMIA; TREATMENT RESPONSE; ULNA; VITAMIN SUPPLEMENTATION;

ADULT; ANEMIA, SICKLE CELL; BONE DENSITY; BONE RESORPTION; CALCIUM CARBONATE; COLLAGEN TYPE I; DRUG THERAPY, COMBINATION; ERGOCALCIFEROLS; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; OSTEOCALCIN; OSTEOMALACIA; OSTEOPOROSIS; PARATHYROID HORMONE; PEPTIDES; PILOT PROJECTS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 41449097387     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21085     Document Type: Article

References (41)

1. Steinberg MH, Adewoye AH. Modifier genes and sickle cell anemia. Curr Opin Hematol 2006;13:131-136.
2. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007;21:37-47.
3. Sarrai M, Duroseau H, D'Augustine J, et al. Bone mass density in adults with sickle cell disease. Br J Haematol 2007;136:666-672.
4. Gurevitch O, Slavin S. The hematological etiology of osteoporosis. Med Hypotheses 2006;67:729-735.
5. Voskaridou E, Stoupa E, Antoniadou L, et al. Osteoporosis and osteosclerosis in sickle cell/β-thalassemia: The role of the RANKL/osteoprotegerin axis. Haematologica 2006;91:813-816.
6. Miller RG, Segal JB, Ashar BH, et al. High prevalence and correlates of low bone mineral density in young adults with sickle cell disease. Am J Hematol 2006;81:236-241.
7. Girasole RV, Lyon ED. Sickle cell osteomyelitis of the mandible: Report of three cases. J Oral Surg 1977;35:231-234.
8. Espinoza LR, Spilberg I, Osterland CK. Joint manifestations of sickle cell disease. Medicine (Baltimore). 1974;53:295-305.
9. Clemens TL, Adams JS, Henderson SL, et al. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1982;1:74-76.
10. Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 2003;78:1463-1470.
11. Looker AC, Dawson-Hughes B, Calvo MS, et al. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 2002;30:771-777.
12. Lal A, Fung EB, Pakbaz Z, et al. Bone mineral density in children with sickle cell anemia. Pediatr Blood Cancer 2006;47:901-906.
13. Buison AM, Kawchak DA, Schall J, et al. Low vitamin D status in children with sickle cell disease. J Pediatr 2004;145:622-627.
14. Mohammed S, Addae S, Suleiman S, et al. Serum calcium, parathyroid hormone, and vitamin D status in children and young adults with sickle cell disease. Ann Clin Biochem 1993;30(Part 1):45-51.
15. Press NA. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D and flouride. The National Academics Press. 1997. www.nap.edu
16. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281.
17. Holick M. Photobiology, metabolism, mechanism of action, and clinical application. In: Favus MJ, editor. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Vol. 4th edition. Philadelphia: Lippincott-Raven; 1999. pp 92-98.
18. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006;84:18-28.
19. Tangpricha V, Pearce EN, Chen TC, et al. Vitamin D insufficiency among free-living healthy young adults. Am J Med 2002;112:659-662.
20. Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 1996;17:333-368.
21. Nolan VG, Adewoye A, Baldwin C, et al. Sickle cell leg ulcers: Associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-β/BMP pathway. Br J Haematol 2006;133:570-578.
22. Madigan C, Malik P. Pathophysiology and therapy for haemoglobinopathies. I. Sickle cell disease. Expert Rev Mol Med 2006;8:1-23.
23. Lee SP, Ataga KI, Orringer EP, et al. Biologically active CD40 ligand is elevated in sickle cell anemia: Potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol 2006;26:1626-1631.
24. Vichinsky EP. The morbidity of bone disease in thalassemia. Ann N Y Acad Sci 1998;850:344-348.
25. Voskaridou E, Anagnostopoulos A, Konstantopoulos K, et al. Zoledronic acid for the treatment of osteoporosis in patients with β-thalassemia: Results from a single-center, randomized, placebo-controlled trial. Haematologica 2006;91:1193-1202.
26. Buchowski MS, de la Fuente FA, Flakoll PJ, et al. Increased bone turnover is associated with protein and energy metabolism in adolescents with sickle cell anemia. Am J Physiol Endocrinol Metab 2001;280:E518-E527.
27. VanderJagt DJ, Bonnett C, Okolo SN, et al. Assessment of the bone status of Nigerian children and adolescents with sickle cell disease using calcaneal ultrasound and serum markers of bone metabolism. Calcif Tissue Int 2002;71:133-140.
28. Teitelbaum SL. Osteoclasts: What do they do and how do they do it? Am J Pathol 2007;170:427-435.
29. Seriolo B, Paolino S, Sulli A, et al. Bone metabolism changes during anti-TNF-α therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006;1069:420-427.
30. Street ME, Spaggiari C, Ziveri MA, et al. Analysis of bone mineral density and turnover in patients with cystic fibrosis: Associations between the IGF system and inflammatory cytokines. Horm Res 2006;66:162-168.
31. Saidenberg-Kermanac'h N, Corrado A, Lemeiter D, et al. TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 2004;35:1200-1207.
32. Omoigui S. The Interleukin-6 inflammation pathway from cholesterol to aging - Role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases. Immun Ageing 2007;4:1.
33. Zhang XZ, Song LG, Li H, et al. [Effects of alendronate on bone mineral density, cytokines and indices of bone metabolism in postmenopausal osteoporotic patients]. Zhonghua Nei Ke Za Zhi 2006;45:565-568.
34. Barton BE. Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes. Expert Opin Ther Targets 2005;9:737-752.
35. Ferrari SL, Karasik D, Liu J, et al. Interactions of interleukin-6 promoter polymorphisms with dietary and lifestyle factors and their association with bone mass in men and women from the Framingham Osteoporosis Study. J Bone Miner Res 2004;19:552-559.
36. Soliman AT, Bererhi H, Darwish A, et al. Decreased bone mineral density in prepubertal children with sickle cell disease: Correlation with growth parameters, degree of siderosis and secretion of growth factors. J Trop Pediatr 1998;44:194-198.
37. Sahota O, Mundey MK, San P, et al. Vitamin D insufficiency and the blunted PTH response in established osteoporosis: The role of magnesium deficiency. Osteoporos Int 2006;17:1013-1021.
38. Olukoga AO, Adewoye HO, Erasmus RT, et al. Urinary magnesium excretion in steady-state sickle cell anasmia. Acta Haematol 1993;90:136-138.
39. Olukoga AO, Adewoye HO, Erasmus RT, et al. Erythrocyte and plasma magnesium in sickle-cell anaemia. East Afr Med J 1990;67:348-354.
40. Binkley N, Bilezikian JP, Kendler DL, et al. Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom 2006;9:4-14.
41. Chen TC, Turner AK, Holick MF. Methods for the determination of the circulating concentration of 25-hydroxyvitamin D. J Nutr Biochem 1990;1:315-319.